Transposagen Biopharmaceuticals, a privately held biotechnology company, has announced plans to move its operations and research facilities from Philadelphia to Lexington.
“Moving from Philadelphia to Lexington has been an important decision in this growth phase of our company,” said Transposagen CEO Dr. Eric Ostertag, noting that the cooperation from state and local government, Commerce Lexington and the University of Kentucky was key to the company’s decision to relocate.
“Lexington is a great example of a city that encourages the growth of technology and life science companies. The state’s commitment to Transposagen will enable us to build our business to a larger scale and add well-paying jobs more quickly.”
Transposagen focuses on providing unique animal models of human diseases for drug discovery and development.